NASDAQ: MBXMbx Biosciences Inc Stock
$56.92-1.62 (-2.77%)
Updated Oct 6, 2026
MBX Price
$56.92
Fair Value Price
$2.05
Market Cap
$2.74B
52 Week Low
$12.94
52 Week High
$72.64
P/E
-24.12x
P/B
6.69x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$104.29M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.06
Operating Cash Flow
-$83M
Beta
1.37
Next Earnings
Nov 5, 2026
Ex-Dividend
N/A
Next Dividend
N/A
MBX Overview
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MBX's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
MBX
Ranked#281 of 459
Ranked#281 of 459
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.50 | A | |
| $7.55 | A | |
| $10.35 | A |
Be the first to know about important MBX news, forecast changes, insider trades & much more!
MBX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MBX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MBX ($56.92) is overvalued by 2,681.96% relative to our estimate of its Fair Value price of $2.05 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
MBX ($56.92) is not significantly undervalued (2,681.96%) relative to our estimate of its Fair Value price of $2.05 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
MBX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more MBX due diligence checks available for Premium users.
Valuation
MBX fair value
Fair Value of MBX stock based on Discounted Cash Flow (DCF)
Price
$56.92
Fair Value
$2.05
Overvalued by
2,681.96%
MBX ($56.92) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MBX ($56.92) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MBX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MBX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-24.12x
Industry
12.56x
Market
51.93x
MBX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.69x
Industry
4.99x
MBX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MBX's financial health
Profit margin
Revenue
$0.0
Net Income
-$37.1M
Profit Margin
0%
MBX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$435.9M
Liabilities
$26.4M
Debt to equity
0.06
MBX's short-term assets ($427.86M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MBX's short-term assets ($427.86M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MBX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$22.6M
Investing
$29.2M
Financing
$2.3M
MBX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MBX vs Biotech Stocks
Mbx Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.